Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
11 Oct 2022
11 Oct 2022
Historique:
received:
07
04
2022
accepted:
01
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with first-line palbociclib plus an aromatase inhibitor (AI) versus an AI alone in routine US clinical practice. In total, 2888 patients initiated treatment during February 3, 2015-March 31, 2020, with a potential ≥6-month follow-up (cutoff date, September 30, 2020). After stabilized inverse probability treatment weighting, median OS (95% CI) is significantly longer among palbociclib versus AI recipients (49.1 [45.2-57.7] versus 43.2 [37.6-48.0] months; hazard ratio, 0.76 [95% CI, 0.65-0.87]; P < 0.0001). Progression-free survival (95% CI) is 19.3 (17.5-20.7) versus 13.9 (12.5-15.2) months, respectively (hazard ratio, 0.70 [95% CI, 0.62-0.78]; P < 0.0001). These data support first-line palbociclib plus an AI treatment for HR+/HER2- MBC.(Trial number NCT05361655).
Identifiants
pubmed: 36220852
doi: 10.1038/s41523-022-00479-x
pii: 10.1038/s41523-022-00479-x
pmc: PMC9553912
doi:
Banques de données
ClinicalTrials.gov
['NCT05361655']
Types de publication
Journal Article
Langues
eng
Pagination
114Informations de copyright
© 2022. Pfizer Inc.
Références
Clin Pharmacol Ther. 2022 Jan;111(1):283-292
pubmed: 34664259
Future Oncol. 2022 Jan;18(3):349-362
pubmed: 34842454
J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9
pubmed: 19903805
Value Health. 2022 Feb;25(2):230-237
pubmed: 35094796
Health Serv Res. 2018 Dec;53(6):4460-4476
pubmed: 29756355
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972
pubmed: 27407089
Cancer Med. 2021 Nov;10(21):7665-7672
pubmed: 34590788
Clin Oncol (R Coll Radiol). 2021 Apr;33(4):e201-e202
pubmed: 33223383
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Clin Pharmacol Ther. 2022 Jan;111(1):11-14
pubmed: 34914104
Target Oncol. 2021 Sep;16(5):601-611
pubmed: 34338965
Breast Cancer (Auckl). 2019 Jan 10;13:1178223418823238
pubmed: 30675102
PLoS One. 2020 Apr 21;15(4):e0227256
pubmed: 32315295
Breast Cancer Res Treat. 2019 Jul;176(2):429-434
pubmed: 30895534
Breast. 2019 Feb;43:22-27
pubmed: 30391832
Cancer Manag Res. 2018 May 04;10:1015-1025
pubmed: 29765249
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Int J Cancer. 2022 Jun 15;150(12):2025-2037
pubmed: 35133007
Pharmacoeconomics. 2018 Mar;36(3):359-368
pubmed: 29214389
JCO Precis Oncol. 2017 Nov;1:1-5
pubmed: 35172519
Future Oncol. 2021 Jun;17(16):2107-2122
pubmed: 33663223
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Clin Transl Gastroenterol. 2014 Jan 02;5:e45
pubmed: 24384867
Health Serv Res. 2021 Dec;56(6):1281-1287
pubmed: 33998685
Cancer Manag Res. 2021 Aug 20;13:6537-6566
pubmed: 34447271
Breast. 2022 Feb;61:118-122
pubmed: 34959093
Breast Cancer Res. 2021 Mar 24;23(1):37
pubmed: 33761995
Clin Cancer Res. 2015 Nov 1;21(21):4760-6
pubmed: 26324739
J Natl Compr Canc Netw. 2019 Feb;17(2):141-147
pubmed: 30787127